Attendee search 

Early stage Biotech investment (VC)

· About Us
Chairman，Mr. Rongguang WU is also the founder of Hongxing Erke , which is one of the most famous sports brands in China. We focus on investing in innovative biotech companies and healthcare funds worldwide. We have an expert team and also seek license-in opportunity of innovative drugs to develop and commercialize in China.

· Investment Cases

Previously, we've invested over 100 million dollars, more than 10 projects worldwide, including VIR Biotechnology, Beijing Genomics institution, GMAX Bio and two Top 10 biomedical funds in America, etc..

· Investment Preference

We don’t have clear limits on the investment scale and the proportion of shares, usually $5 million to $20 million of a single investment. Companies in initial stage to growth stage are all in our consideration. We can lead, co-lead, or join a round that others are leading.

Website：www.hongxingerke.com

Founded in 2007, T&W Group specializes in developing, manufacturing and supplying fine chemicals in Pharmaceuticals, Agrochemicals, Photosensitive Materials, UV Curing Coatings, Brightener, OLED & Electronic Chemicals and other specialty chemicals. We also have R&D center focusing on CDMO projects for our customer.

Stanford Genome Technology Center

Leading Investment and security company in China

天士力

Liquid biopsy blood test for early detection of cancers

VISEN Pharmaceuticals, headquartered in Shanghai, China, is committed to the treatment of endocrine-related disease, introducing the world’s leading treatment methods and drugs into the China market, benefiting Chinese patients while unleashing product potential.

VISEN Pharmaceuticals (VISEN) was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma’s endocrinology rare disease therapies in Greater China. The pipeline of VISEN covers pediatric endocrinology, adult endocrinology, and rare disease. VISEN management team has extensive experience in the development and commercialization of endocrine disease products in Greater China. VISEN has a deep understanding of unmet medical needs in Chinese patients and is actively expanding its pipeline through in-licensing and partnership.

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.